- $11.45bn
- $16.05bn
- $4.38bn
- 71
- 30
- 60
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 48.92 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.23 | ||
| Price to Tang. Book | 31.36 | ||
| Price to Free Cashflow | 115.64 | ||
| Price to Sales | 2.59 | ||
| EV to EBITDA | 40.12 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.03% | ||
| Return on Equity | -11.19% | ||
| Operating Margin | -2.04% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3,094.3 | 3,998 | 4,802 | 4,263 | 4,381 | 4,667.59 | 5,043.66 | 11.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +6.34 | +68.58 | +25.03 | -98.61 | n/a | n/a | +36.68 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides formulation, development, and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for oral solid doses forms, softgels, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms. It also provides formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.
Directors
- John Chiminski CHM (57)
- Alessandro Maselli PRE (49)
- Thomas Castellano CFO (41)
- Jonathan Arnold CEX (55)
- Karen Flynn CEX (57)
- Aristippos Gennadios CEX (55)
- Ricci Whitlow CEX (52)
- Ricardo Pravda CHO (49)
- Charles Lickfold SVP
- Steven Fasman SVP (58)
- Michael Grippo SVP (51)
- Scott Gunther SVP (53)
- Kay Schmidt SVP (62)
- Z Mahdavi VPR
- Jack Stahl LED (68)
- Madhavan Balachandran IND (70)
- Michael Barber IND (61)
- J. Martin Carroll IND (71)
- Rolf Classon IND (76)
- Rosemary Crane IND (61)
- John Greisch IND (66)
- Christa Kreuzburg IND (62)
- Gregory Lucier IND (57)
- Donald Morel IND (64)
- Peter Zippelius IND (42)
- Last Annual
- June 30th, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- March 14th, 2007
- Public Since
- July 31st, 2014
- No. of Shareholders
- 7
- No. of Employees
- 16,900
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 181,511,586
- Address
- 14 Schoolhouse Rd, SOMERSET, 08873-1213
- Web
- https://www.catalent.com/
- Phone
- +1 7325376200
- Auditors
- GRANT THORNTON LLP (US)
Latest News for CTLT
Upcoming Events for CTLT
Catalent Inc Annual Shareholders Meeting
Q2 2025 Catalent Inc Earnings Release
Q3 2025 Catalent Inc Earnings Release
Similar to CTLT
Abbvie
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
FAQ
As of Today at 18:48 UTC, shares in Catalent are trading at $63.07. This share price information is delayed by 15 minutes.
Shares in Catalent last closed at $63.07 and the price had moved by +52.49% over the past 365 days. In terms of relative price strength the Catalent share price has outperformed the S&P500 Index by +18.93% over the past year.
The overall consensus recommendation for Catalent is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCatalent does not currently pay a dividend.
Catalent does not currently pay a dividend.
Catalent does not currently pay a dividend.
To buy shares in Catalent you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $63.07, shares in Catalent had a market capitalisation of $11.45bn.
Here are the trading details for Catalent:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: CTLT
Based on an overall assessment of its quality, value and momentum Catalent is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Catalent is $63.43. That is 0.57% above the last closing price of $63.07.
Analysts covering Catalent currently have a consensus Earnings Per Share (EPS) forecast of $1.10 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Catalent. Over the past six months, its share price has outperformed the S&P500 Index by +2.82%.
As of the last closing price of $63.07, shares in Catalent were trading +8.5% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Catalent PE ratio based on its reported earnings over the past 12 months is 48.92. The shares last closed at $63.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Catalent's management team is headed by:
- John Chiminski - CHM
- Alessandro Maselli - PRE
- Thomas Castellano - CFO
- Jonathan Arnold - CEX
- Karen Flynn - CEX
- Aristippos Gennadios - CEX
- Ricci Whitlow - CEX
- Ricardo Pravda - CHO
- Charles Lickfold - SVP
- Steven Fasman - SVP
- Michael Grippo - SVP
- Scott Gunther - SVP
- Kay Schmidt - SVP
- Z Mahdavi - VPR
- Jack Stahl - LED
- Madhavan Balachandran - IND
- Michael Barber - IND
- J. Martin Carroll - IND
- Rolf Classon - IND
- Rosemary Crane - IND
- John Greisch - IND
- Christa Kreuzburg - IND
- Gregory Lucier - IND
- Donald Morel - IND
- Peter Zippelius - IND